Pharm Exec’s 2020 Pipeline Report

In this ISSUE

Biosensors in Pharma: A Does of Optimism

Closing the Manufacturing and Science Divide

Trends in Payer Reliance on ICER Assessments

TOP FEATURE

Pharm Exec’s Pipeline Report 2020

Our Annual Pipeline Report examines six key areas of biopharma R&D where promising research efforts are now beginning to pay dividends, as novel advances in science usher in new treatment approaches and curative therapies.
… /Read more/

Regulatory

Debate Heats Up Over Reference Pricing Plan

Measure would cut drug costs, slash revenues, curb R&D. Jill Wechsler reports.
… /Read more/

Successful Integration of First- and Third-Party HCP Promotion - How to navigate regulatory and reimbursement approval
Check out this article to discover important keys to effective integration of first- and third-party HCP promotion.
Read the article

Calendar

/ November 13–14: 6th Annual Global Compliance Congress /

London, UK

/ December 4–5: Trade and Channel Strategies /

Philadelphia, PA.

/ December 11¬–12: Pharmaceutical Drug Pricing Strategies Summit /

Washington, DC

/ December 11: Clinical Trial Financial Management /

Philadelphia, PA

/ March 18–19 2020: World Pharma Pricing Market Access & Evidence Congress /

Amsterdam, The Netherlands

RECRUITMENT & RETENTION

Navigating the Future of Talent

Rebecca Cenni-Leventhal outlines some ways that pharmaceutical companies are staying ahead of the talent curve.
… /Read more/

ACCESS TO MEDICINES

Does Formulary Contracting Mean Patients Will Get Their Prescriptions?

Dan Rubin looks at the communication disconnect between contracting with managed care plans and pharmaceutical benefit managers and the implications of prior authorization requirements.
… /Read More/

Order-To-Cash Management Fundamentals to Increase Profitability and Reduce Risk
Wednesday, November 20, 2019 at 10am EST| 9am CST| 3pm GMT| 4pm CET
Read the article

AUDIO

The Pharm Exec Podcast: Pharma Reputation

Sven Klingemann, research director at Reputation Institute, talks about pharma’s negative public perception and what the industry can do to improve it.
… /Click here to listen/

Industry update

// Peter Griffith was appointed as Executive Vice President, Finance at Amgen. He will become the company’s Chief Financial Officer, succeeding current CFO David Meline, on January 1, 2020. // Mike Mason will become Senior Vice President of Lilly and President of Lilly Diabetes and Lilly USA on January 1, 2020. He succeeds Enrique Conterno, who will retire from the role at the end of the year. // Former Pfizer Executive Thomas G. Heffner, Ph.D., joined biotech company Akelos (New York, NY) as a Strategic Advisor. // Orion Biotechnology Canada (Ottawa, Ontario) announced that Dr. Thomas Hecht has been appointed Chairman of its Board of Directors. // Mundipharma Pharmaceuticals Limited (Dublin, Ireland) announced the appointment of Matthew Homent as Ireland Country Manager, a position he has held on an interim basis since April 2019.

A Modern Approach to Global Growth & Compliance in Life Sciences: A Story of Digitalization at Boehringer Ingelheim
November 13, 2019 at 2pm EDT | 1pm CDT | 11am PDT
Read the article

advertise with us / print subscribe / digital subscribe / visit pharmexec.com